No description available.

No description available.

La Fibrose Pulmonaire Idiopathique (FPI) est une pathologie pulmonaire chronique, progressive, irréversible et mortelle, dont les thérapeutiques sont insuffisantes à ce jour. L'activation de la cascade de la coagulation et des protéases à sérine, délétère dans la progression des maladies pulmonaires chroniques, est une caractéristique de la pathologie. Récemment, un lien a été démontré entre Protease-Activated Receptor-2 (PAR-2), un récepteur cellulaire ubiquitaire, et la progression de la fibrose pulmonaire chez l'homme et la souris. Outre certains facteurs de la coagulation, PAR-2 semble aussi pouvoir être activé par des protéases appartenant à la famille récemment identifiée des Type II Transmembrane Serine Proteases (TTSPs), dont la matriptase et la Human Airway Trypsin-like protease (HAT). Leur rôle dans la fibrogénèse pulmonaire humaine et expérimentale est cependant encore inconnu.Nos travaux montrent pour la première fois qu'il existe une dérégulation de l'expression et de l'activité de ces protéases de la famille des TTSPs chez le patient FPI. In vitro, la matriptase induit des réponses pro-fibrosantes dans les fibroblastes pulmonaires primaires humains via l'activation de PAR-2, tandis que la HAT induit des réponses anti-fibrosantes dans ces cellules et une activation de la voie de la prostaglandine E2. Ces deux TTSPs sont ainsi différemment impliquées dans la fibrogénèse pulmonaire : in vivo, l'inhibition génétique et pharmacologique de la matriptase atténue la fibrose dans le modèle murin de fibrose pulmonaire induite par la bléomycine, et des résultats similaires sont observés suite à la surexpression de la HAT médiée par adénovirus dans ce modèle animal. L'ensemble des résultats obtenus dans ce travail de thèse permet de documenter l'implication de deux protéases à sérine, la matriptase et la HAT, dans la pathogénèse de la FPI et de définir des axes de recherche thérapeutique potentiels / Idiopathie Pulmonary Fibrosis (IPF) is a chronic, progressive, irreversible and mortal disease. Therapeutics options that improve the clinical outcome of IPF are limited. Coagulation proteinases and coagulation signaling deregulation, which influences several key inflammatory and fibroproliferative responses, is essential in IPF. Recently, Protease-Activated Receptor-2 (PAR-2) was shown to be involved in pulmonary fibrogenesis, both in Human and in mice. In addition to coagulation factors, PAR-2 can be activated by serine proteases of the emerging Type II Transmembrane Serine Proteases (TTSPs) family, including matriptase and the Human Airway Trypsin-like protease (HAT). Herein we explored the role of matriptase and HAT in the progression of human and experimental pulmonary fibrosis.Our data show that TTSPs matriptase and HAT pulmonary expression and activity are deregulated in patients with IPF. In vitro, matriptase induces PAR-2 dependent pro-fibrotic responses in primary human lung fibroblasts, whereas HAT induces anti-fibrotic effects in these cells, through the activation of prostaglandin E2 pathway. These TTSPs are differently involved in pulmonary fibrogenesis: in vivo, genetic and pharmacological inhibition of matriptase reduces fibrosis in the bleomycin induced lung fibrosis model, while an adenovirus-mediated HAT overexpression in the murine model leads also to a limited lung fibrosis. Here, we highlight the involvement of matriptase and HAT in the pathogenesis of IPF and explore potential therapeutics for lung fibrosis

No description available.

La fibrose kystique (FK) est caractérisée par une inflammation pulmonaire chronique. Cette dernière est définie entre autres par une augmentation importante de la production de mucus. Celui-ci s'accumule dans les bronches empêchant ainsi l'éventuel passage de l'air. De plus, le mucus forme une barrière protectrice pour les bactéries qui va causer l'inflammation des poumons. La protéase human airway trypsin-like (HAT) a été retrouvée dans les expectorations de patients atteints d'asthme et bronchite chronique, pathologies similaires à la FK. Elle semble jouer un rôle dans l'inflammation car elle augmente entre autres la production de MUC5AC, protéine composant majoritairement le mucus. Le but de cette étude était de synthétiser la HAT dans une conformation active dans un système eucaryote pour étudier ses propriétés biochimiques, enzymatiques ainsi que son potentiel pro-inflammatoire dans la lignée cellulaire pulmonaire Calu-3. L'ADNc codant pour la partie soluble de la HAT a été inséré dans le vecteur pMT-BiP V5-His. Cet ADN recombinant fut ensuite transfecté dans les cellules de Drosophile Schneider 2 (S2). La HAT recombinante a par la suite été purifiée et son activité protéolytique testée avec un substrat fluorogénique. Ses propriétés biochimiques et enzymatiques ont été étudiées ainsi que son effet sur la production d'IL-8 et sa détection dans les expectorations de patients. La HAT purifiée était «enzymatiquement» pure, donc l'effet protéolytique observé avec le substrat fluorogénique est dû à la protéase. Les analyses de ses propriétés biochimiques montrent que l'activité protéolytique de la HAT est inhibée par un pH acide (<6.5), certains inhibiteurs synthétiques (l'aprotinine, la leupeptine et le PEFABLOC) et endogène (i.e: alpha-2 anti-plasmine (a2-AP)) de protéases à sérine. D'un autre côté, les essais enzymatiques révèlent que la HAT a une préférence pour les substrats ayant une arginine en P4, P3 et Pl plutôt que ceux ayant un glutamate en P4, P2 et P1'. Finalement, l'étude sur l'implication physiologique de l'enzyme démontre que la protéase ne semble pas avoir d'effet ou au plus peu d'effet sur la production d' IL-8. [Symboles non conformes]

Increased airway smooth muscle (ASM) mass contributes to airway hyperresponsiveness (AHR) in asthma and is orchestrated by growth factors, cytokines and chemokines. Airway contractile responses are influenced by neuromediators, such as acetylcholine, and glutamate released by parasympathetic and sympathetic airway nerves. Hyperactivity of these neural elements, termed neurogenic inflammation, is linked with hypercontractility and AHR. Glutamate is a non-essential amino acid derivative, and its physiological role is traditionally considered with respect to its being the primary excitatory neurotransmitter in brain, and regulation of neuronal development and memory. In allergic inflammation, immune cells including dendritic cells, neutrophils and eosinophils, constitutively synthesize and release glutamate, which signals through activation of glutamate receptors, most important among which are ionotrophic N-methyl D-aspartate receptors (NMDA-R). We hypothesized that glutamatergic signaling mediated through NMDA-Rs plays an important role in inducing functional Ca2+ responses in human (H) ASM cells that can underpin airway hypercontractility. We investigated the expression and function of NMDA-Rs in HASM cells, and assessed the effects of pro-inflammatory cytokines on NMDA-R expression and functional responses. Moreover, we measured airway responses to NMDA in mice, murine thin cut lung slice preparations, and floating collagen gels seeded with HASMs. Our data reveal that airway myocytes express multi-subunit NMDA-R complexes that function as receptor-operated calcium channels (ROCCs), mobilizing intracellular Ca2+ in ASM in vitro and airway contraction ex vivo. Individual airway myocytes treated with NMDA-R agonist exhibit disparate temporal patterns of intercellular Ca2+ flux that can be partitioned into four discrete function sub-groups. Further we show that tumor necrosis factor (TNF) exposure modulates NMDA-R subunit expression, and these changes are associated with a shift in the distribution of myocytes in individual Ca2+-mobilization sub-groups in vitro. Further, post-TNF exposure, NMDA-R agonists’ treatment induced Ca2+-dependent airway dilation in murine lung slice preparations, an effect that was prevented by co-treatment with inhibitors of nitric oxide synthase (NOS) or cyclooxygenase (COX). Taken together, we conclude that NMDA-R regulate HASM-mediated airway contraction and their role can be affected upon exposure to asthma-associated inflammatory mediators. Thus, NMDA-Rs are of relevance to mechanisms that determine airway narrowing and AHR associated with chronic respiratory diseases. / October 2015

Chitosan is a biocompatible and biodegradable mucoadhesive polymer with unique advantages, such as the distinct trait of opening the junctions to allow paracellular transport of antigen and good tolerability. However, the poor solubility of chitosan in neutral or alkalinized media has restricted its applications in the pharmaceutical field. Chitosan can be easily carboxymethylated to improve its solubility in aqueous media, while its biodegradability and biocompatibility are preserved. Apart from this, carboxymethyl chitosan (CMCS) can be easily processed into nanoparticles which highlight its suitability and extensive usage for preparing different drug delivery formulations. The present study deals with the development and characterization of a delivery system based on CMCS nanoparticles using ovalbumin as model protein. We demonstrated that ovalbumin loaded nanoparticles were successfully synthetized using calcium chloride as a cross-linker by ionic gelation. The nanoparticles exhibited an average size of approximately 169 nm and presented a pseudo-spherical shape. The nanoparticles size increased according to the addition of CaCl2 due to the strong electrostatic attraction. During storage the nanoparticles size increased was attributed to swelling and aggregation. The loading efficiency of ovalbumin was found to be 17%. Confocal microscopy clearly showed the association between ovalbumin and CMCS chains into nanoparticles. Therefore, we suggest these nanoparticles can be considered as an attractive and promising carrier candidate for proteins and antigens. The major challenge that limits the use of such carriers is their instability in an aqueous medium. Thus, the next step of this work was to determine the robustness of several formulations using distinct freeze-drying protocols. This study demonstrated that mannitol in concentration of 10% (w/v) is well suited to preserve ovalbumin loaded CMCS nanocapsules from aggregation during lyophilization and subsequent reconstitution. Importantly, the results showed that an annealing step has a huge impact on porosity of freeze-dried cake by nearly complete crystallization of mannitol, once the crystalline matrix prevents the partial collapse and the formation of larger pores observed without annealing. Therefore, the usual observation that annealing increases the pore size due to growth of ice crystal size does not always apply, at least when crystallization of solute is involved. Since all characterizations and stability studies had been performed, the main purpose of this study was to develop a stable antigen delivery system for oral immunization using CMCS and inactivated rabies virus (RV) as the antigen. RV loaded nanoparticles was found to enhance both systemic (IgG) and local (IgA) immune responses against RV after oral delivery in mice. The effective doses 50% were 50-times higher than the negative controls, indicating that the immune response started only after the third boosting dose. Furthermore, enough neutralizing antibodies was produced to be protected against the harmful effects of the rabies virus. It is therefore concluded, that the CMCS nanoparticles formulated in this study, are suitable for oral vaccine delivery, and can be suggested as a promising delivery system for a diverse range of antigens as well as a gene/protein delivery system, especially for those positively charged. Since several approaches show that effective intervention in airway allergic inflammation can be achieved with allergen-activated interleukin-10-secreting cells, the final part of this work was dedicated to assessing whether IL-10 loaded chitosan nanoparticles (IL10-CSNPs) could be used as a possible inhalable therapeutic tool for preventing exacerbations in asthmatic patients. As positive controls, we also assess whether interleukin 17A and interleukin 9 have the ability to stimulate human airway smooth muscle (HASM) cell contractility using magnetic twisting cytometry (MTC). Significant decreased baseline cell stiffness was observed in HASM cells pre-treated with IL-10, but not with IL10-CSNPs, whereas treatment with IL-17A significantly enhanced baseline cell stiffening. Our findings reveal a previously unknown mechanism underlying immunotherapy for prevention and treatment of asthma. / A quitosana é um polímero mucoadesivo biocompatível e biodegradável, com vantagens únicas, tais como a característica distinta de abrir as junções que permitim o transporte paracelular de antígenos e boa tolerabilidade. No entanto, sua baixa solubilidade em meios neutros ou alcalinizados tem restringido suas aplicações no campo farmacêutico. A quitosana pode ser facilmente carboximetilada para melhorar de sua solubilidade em meios aquosos, enquanto sua biodegradabilidade e biocompatibilidade são preservadas. Além disso, a carboximetilquitosana (CMCS) pode ser facilmente processada na forma de nanopartículas, o que destaca sua adequabilidade para uso extensivo no preparo de sistemas de delivery de medicamentos. O presente estudo trata do desenvolvimento e caracterização de um sistema de delivery baseado em nanopartículas de CMCS utilizando ovalbumina como proteína modelo. Nós demonstramos que as nanopartículas carregadas com ovalbumina foram sintetizadas com sucesso utilizando cloreto de cálcio como agente de reticulação por gelificação iônica. As nanopartículas exibiram um tamanho médio de aproximadamente 169 nm e apresentaram uma forma pseudo-esférica. O tamanho das nanopartículas aumentou de acordo com a adição de CaCl2 devido à forte atração eletrostática. Durante o armazenamento, o tamanho aumentado das nanopartículas foi atribuído a incorporação de água e agregação. A eficiência de encapsulamento da ovalbumina foi de aproximadamente 17%. A microscopia confocal mostrou claramente a associação entre ovalbumina e a cadeias de CMCS nas nanopartículas. Sugerimos, portanto, que tal sistema pode ser considerado como candidato atraente e promissor para o carreamento de proteínas e antígenos. O principal desafio que limita o uso desses carreadores consiste na instabilidade em meio aquoso. Assim, o próximo passo deste trabalho foi determinar a robustez de várias formulações utilizandose diferentes protocolos de liofilização. Este estudo demonstrou que o manitol em uma concentração de 10% (p/v) é adequado para preservar da agregação as nanocápsulas de CMCS carregadas com ovalbumina durante a liofilização e subsequente reconstituição. Mais importante, os resultados mostraram que uma etapa de annealing tem um enorme impacto sobre a porosidade da amostra liofilizada devido a quase completa cristalização do manitol, uma vez que a matriz cristalina evita o colapso parcial e a formação de poros maiores observados na ausência do annealing. Portanto, a observação comum de que o annealing aumenta o tamanho doporos devido ao crescimento dos cristais de gelo nem sempre se aplica, pelo menos quando a cristalização de um soluto está envolvida. Uma vez que todas as caracterizações e estudos de estabilidade foram realizados, o principal objetivo deste estudo foi desenvolver um sistema estável de delivery de antígeno para imunização oral utilizando CMCS e vírus rábico inativado (RV) como antígeno. Verificou-se que as nanopartículas carregadas com RV aumentam as respostas imune sistêmica (IgG) e local (IgA) contra o RV após administração oral em camundongos. As doses efetivas 50% foram 50 vezes maiores que os controles negativos, indicando que a resposta imune foi iniciada apenas após a terceira dose da vacina. Além disso, foram produzidos anticorpos neutralizantes suficientes para proteção contra os efeitos nocivos do vírus rábico. Conclui-se, portanto, que as nanopartículas de CMCS formuladas neste estudo, são adequadas para o delivery oral de vacinas, e podem ser sugeridas como um sistema promissor de delivery para uma gama diversa de antígenos, bem como para o delivery de genes/proteínas, especialmente para aqueles carregados positivamente. Uma vez que diversas abordagens mostram que uma intervenção efetiva em casos de inflamação alérgica de vias aéreas pode ser conseguida por meio de células secretoras de interleucina 10 (IL-10) mediante ativação por alergenos, a parte final deste trabalho esteve dedicada a avaliação de nanopartículas de quitosana carregadas com IL-10 (IL10-CSNPs) como possível ferramenta terapêutica inalável para prevenção de exacerbações em pacientes asmáticos. Como controles positivos, avaliou-se adicionalmente se as interleucinas 17A (IL-17A) e 9 (IL-9) possuem a capacidade de estimular a contratilidade de células humanas de músculo liso de vias aéreas humanas (HASM) por meio de citometria de torção magnética (MTC). Uma diminuição significativa da rigidez celular basal foi observada em células HASM pré-tratadas com IL-10, mas não com IL10-CSNPs, enquanto que o tratamento com IL-17A aumentou significativamente a magnitude rigidez celular basal. Nossos resultados revelam um mecanismo previamente desconhecido subjacente à imunoterapia para prevenção e tratamento da asma.

Chez les vertébrés, le battement coordonné des cils motiles présents par centaines à la surface apicale des cellules multiciliées (MCC) est requis pour propulser directionnellement les fluides biologiques à l’intérieur de certains organes (voies respiratoires, ventricules cérébraux, trompes utérines ou certaines structures embryonnaires). De nombreuses pathologies humaines sont associées à des défauts ciliaires ou à une perte des MCC (dyskinésies ciliaires, mucoviscidose, asthme,...). Dans ce contexte, mon travail de thèse a consisté à élucider les mécanismes complexes contrôlant la différenciation des MCC et donc la formation des cils motiles (multiciliogenèse). Par des approches de génomiques fonctionnelles à partir de deux modèles d’épithéliums multiciliés évolutivement éloignés (épithélium respiratoire humain et épiderme d’embryon de Xénope) nous avons identifié la famille des microARN (petits ARN non-codants régulateurs de l’expression génique) miR-449 comme majoritairement exprimée dans les MCC. Nous avons montré que miR-449 contrôle la multiciliogenèse i) en bloquant le cycle cellulaire, ii) en réprimant directement la voie de signalisation Notch et iii) en inhibant l’expression de la petite GTPase R-Ras. Enfin, nos travaux montrent que l’ensemble de ces mécanismes est conservé chez les vertébrés. En conclusion, miR-449 est un nouveau régulateur clé de la multiciliogenèse conservé au cours de l’évolution. Nos résultats pourraient ouvrir la voie à de nouvelles stratégies thérapeutiques utilisant des petits ARN régulateurs dans le traitement de certaines pathologies associées à des défauts ciliaires. / In vertebrates, the coordinated beating of hundreds of motile cilia present at the apical surface of multiciliated cells (MCC) is required for propel directionally flow of biological fluids inside some organs (airways, cerebral ventricles, fallopian tubes or some embryonic structures). Many human diseases are associated with ciliary defects or loss of MCC (ciliary dyskinesia, cystic fibrosis, asthma ...). In this context, my thesis has sought to elucidate the complex mechanisms that control the differentiation of MCC and thus the formation of motile cilia (multiciliogenesis). By functional genomic approaches from two evolutionarily distant models of multiciliated epithelia (human respiratory epithelium and epidermis of Xenopus embryo) we identified the miR-449 family of microRNAs (small non-coding RNAs regulating gene expression) as mainly expressed in MCC. Then, we showed that miR-449 controlled multiciliogenesis by i) blocking the cell cycle ii) directly suppressing the Notch pathway and iii) by inhibiting the expression of the small GTPase R-Ras. Finally, we have demonstrated that all these mechanisms were conserved in vertebrates. In conclusion, miR-449 is a new key and conserved regulator of multiciliogenesis. Our findings could pave the way for new therapeutic strategies using small regulatory RNAs in the treatment of several diseases associated with ciliary defects.

L’augmentation de la prévalence mondiale des pathologies respiratoires et allergiques depuis la seconde moitié du 20ème siècle ainsi que l’émergence de symptômes spécifiques liés à des environnements clos dans les années soixante-dix, ont contribué à incriminer l’exposition à la pollution de l’air intérieur, en particulier aux composés organiques volatils (COV), comme facteur de risque dans l’apparition de ces pathologies. Les différentes approches épidémiologiques et expérimentales existantes ont permis de renseigner la composition, les sources, les déterminants et les effets de cette pollution en particulier sur l’appareil respiratoire humain, première voie d’exposition. A l’heure actuelle, les politiques expérimentales visent à substituer les expérimentations animales par le développement de méthodes alternatives, dont les méthodes in vitro, pour des raisons économiques et éthiques. Cependant, les modèles in vitro permettant l’étude des polluants environnementaux sur les cellules de l’arbre respiratoire sont encore peu développés. L’objectif de cette thèse est donc de proposer une approche expérimentale in vitro adaptée à l’étude d’impact des expositions de cellules épithéliales nasales humaines à des polluants environnementaux, en particulier les COV. La force de ce travail est d’avoir mis en place des méthodologies approchant les conditions réelles d’exposition, et de les avoir appliquées à des atmosphères d’environnement intérieur. Au terme de ces travaux, les acquis méthodologiques ont porté sur le modèle de cellules épithéliales nasales évoluant de la culture primaire à l’épithélium reconstitué, constitué de plusieurs types cellulaires, proche de l’épithélium respiratoire humain ; la génération d’atmosphère chargée en mono (formaldéhyde) ou multi-polluants (COV issus de peinture du commerce), et surtout son contrôle analytique, étape essentielle pour valider notre démarche expérimentale ; l’exposition répétée (jusqu’à 3 par semaine, de durée allant jusqu’à 2 heures, sur une période totale d’au moins un mois) en interface air-liquide, sans perte d’intégrité cellulaire, dynamique (sous flux d’air) pour les polluants gazeux, ou statique (sans flux) pour dépôt des particules ; l’étude morphologique et histologique de l’épithélium, développée comme marqueur d’effet complétant l’approche biologique centrée sur la réponse inflammatoire. L’exposition au formaldéhyde gazeux à une concentration proche des niveaux environnementaux intérieur, n’a pas eu d’effet sur les marqueurs de l’inflammation. Lors de l’exposition de l’épithélium reconstitué choisi (MucilAirTM, Société Epithelix) aux COV, une inhibition de la production spécifique d’IL-8 dépendant de la dose et du nombre d’exposition est observée, alors que l’intégrité tissulaire de l’épithélium n’est pas altérée. Le mécanisme de cette inhibition demande à être exploré plus avant. Pour autant, la réactivité du modèle, en matière de réaction inflammatoire et de changement de structure de l’épithélium a été validée lors d’expositions à un mélange environnemental complexe (particules de fumée de tabac). Notre approche in vitro innovante peut être élargie à l’étude d’autres atmosphères multi-polluants (chimiques, physiques et biologiques) afin d’être au plus proche des conditions réelles d’expositions, mais aussi à d’autres organes cibles. / Increase of respiratory diseases since the second half of the 20th century and emergence of specific symptoms related to closed environments contributed to suspect indoor air pollution, in particular volatile organic compounds (VOC), as a risk factor in the onset of these diseases. Epidemiological and experimental approaches are useful to determine its sources, determinants and effects on the human respiratory tract. Current experimental policies favor replacing animal experiments by alternative methods like in vitro methodologies, for economic and ethical reasons. Until now, in vitro models have been poorly developed to study environmental pollutants on respiratory cells. The objective of our work was to propose an experimental approach adapted to the study of the impact of environmental pollutants, particularly VOC, on human nasal epithelial cells. The strength of this work is to set up a methodology close to actual conditions of exposure, and apply them to indoor environment atmospheres. The methodology developed aimed to study reconstituted epithelium coming from primary culture of nasal cells, composed of several cell types, close to human respiratory epithelium; generate atmosphere charged with mono (formaldehyde) or multi-pollutant (VOC paint), and especially its analytical control (an essential step to validate our experimental approach); and repeated exposure (3 per week, until to two hours, over a total period of one month) at air-liquid interface without loss of cellular integrity, in dynamic conditions (under airflow) for gaseous pollutants, or static (without airflow) for particles. The setup of a morphological and histological approach allowed to complete biological effect (inflammatory response). Gaseous formaldehyde exposure at low concentration had no effect on inflammatory markers. VOC exposures on selected reconstituted epithelium (MucilAirTM, Epithelix Company) showed a decreased release of IL-8 depending on the dose and the number of exposure, without tissue damage. The mechanism of this effect needs to be further investigated. Responsiveness of the model, in terms of inflammation and structural changes of the epithelium was validated by assessing complex environmental mixture (tobacco smoke particles). Our innovative in vitro approach can be extended to the study of other multi-pollutant atmospheres (chemical, physical and biological) in order to get close to the actual conditions of exposure, but also by using other target organs.

No description available.